Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study

详细信息    查看全文

• 作者：Hé ; lè ; ne Guet-Revillet^a ; ^b ; ¹ ; Elise Tomini^b ; ¹ ; Auré ; lie Emirian^c ; ^d ; Olivier Join-Lambert^a ; ^b ; Hervé ; Lé ; cuyer^a ; ^b ; Jean-Ralph Zahar^e ; ^f ; ² ; ^{jrzahar@gmail.com} ; Vincent Jullien^g ; ^h
• 关键词：Piperacillin ; Tazobactam ; ESBL ; UTI ; Pyelonephritis
• 刊名：International Journal of Antimicrobial Agents
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：49
• 期：1
• 页码：62-66
• 全文大小：765 K
• 卷排序：49

文摘

Piperacillin/tazobactam for ESBL-PE UTI was evaluated by Monte Carlo simulation. Continuous infusion or 4.5 g four times daily as a 4-h infusion appears convenient for mild pyelonephritis. Continuous infusion should be preferred for severe pyelonephritis due to ESBL-Kp.